Technology

The Problem

Conventional manufacturing technology is scaled for mass production at large volumes. This results in a process that is labor intensive, high cost per batch, and highly wasteful. Additionally, there is a long turnaround time from production and testing to releasing and shipping the final product. This lends current biologics manufacturing to favor far-reaching diseases where larger volume costs are justified.

The Opportunity

Highly potent and targeted therapies are less suited for mass production. Small batch manufacturing is more properly scaled for demand, resulting in lower manufacturing cost and less waste.

Fully Enabled Technology

Decreases batch costs
Decreases turnaround time
Reduces manual labor
Reduces supply chain complexity
Increases access to targeted therapies